MARKET

VCYT

VCYT

Veracyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.19
-3.01
-5.88%
After Hours: 48.19 0 0.00% 16:37 09/20 EDT
OPEN
49.31
PREV CLOSE
51.20
HIGH
50.07
LOW
47.57
VOLUME
473.54K
TURNOVER
--
52 WEEK HIGH
86.03
52 WEEK LOW
28.82
MARKET CAP
3.41B
P/E (TTM)
-47.7554
1D
5D
1M
3M
1Y
5Y
ABCL, TCRR, KYMR and GRTS among after hours movers
Gainers: ABCL +19.8%. TCRR +7.4%. ATAI +6.7%. FANG +4.9%. VCYT +4.7%. Losers: KYMR -7.6%. GRTS -5.1%. JNCE -4.4%. GDS -3.4%. AMTX -3.3%.
Seekingalpha · 4d ago
BRIEF-Veracyte Announces That New NCCN Guidelines Uniquely Recommend Use Of Decipher Prostate Genomic Test Score To Guide Specific Treatment For Men Following Radical Prostatectomy
reuters.com · 6d ago
Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
Veracyte, Inc. (Nasdaq: VCYT) today announced that its Decipher(R) Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network(R) (NCCN) Clinical Practice Guidelines for Oncology to guide treatment decisions for...
Business Wire · 6d ago
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Sept. 10, 2021: VCYT, CRSP, SPFR, MKFG, RPTX, NVTA, PSNL, ADPT
Veracyte (VCYT) - 45,484 CRISPR Therapeutics (CRSP) - 17,000  Jaws Spitfire Acquisition Corp (SPFR) - 318482 Markforged Holding Corp (MKFG) - 174,225  Repare Therapeutics (RPTX)
Benzinga · 09/13 14:52
Insider Sell: Veracyte
MT Newswires · 09/09 17:17
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Sept. 8, 2021: PATH, NVTA, FATE, PD, DE, MKFG, KMTUY, SPFR, ROKU, SPLK, KVSB, ADPT, SLGC, VCYT, PSNL, RPTX, ETSY, FTCH, STNE, Z, JD, HEI, BLDE, AVAV
UiPath (PATH) - 1,382,967 Shares Invitae (NVTA) - 616,413 Fate Therapeutics (FATE) - 129,739 PagerDuty (PD) - 55,058 Deere & Co (DE) - 37,991 Markforged (MKFG) - 600,664 Komatsu (KMTUY) - 96,118 Jaws
Benzinga · 09/09 13:58
Artisan Partners: “Veracyte (VCYT) is Well-Positioned to Expand Internationally”
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 4.36% was recorded by its Investor Class: ARTSX, 4.40% by its ...
Insider Monkey · 09/06 17:22
Advisors' Inner Circle Fund II Buys Steris PLC, Sumo Logic Inc, ESCO Technologies Inc, Sells , ...
GuruFocus News · 09/04 06:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VCYT. Analyze the recent business situations of Veracyte through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VCYT stock price target is 63.17 with a high estimate of 95.00 and a low estimate of 42.00.
EPS
Institutional Holdings
Institutions: 314
Institutional Holdings: 78.41M
% Owned: 110.66%
Shares Outstanding: 70.85M
TypeInstitutionsShares
Increased
80
7.86M
New
33
1.67M
Decreased
66
4.70M
Sold Out
51
4.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Executive Director
Bonnie Anderson
Chief Executive Officer/Director
Marc Stapley
Chief Financial Officer
Rebecca Chambers
Executive Vice President
Robert Brainin
Senior Vice President/Chief Information Officer
Bill Zondler
Chief Accounting Officer/Vice President/Controller
Beverly Alley
Chief Scientific Officer
Giulia Kennedy
Lead Director/Independent Director
John Bishop
Independent Director
Muna Bhanji
Independent Director
Frederick Cohen
Independent Director
Karin Eastham
Independent Director
Robert Epstein
Independent Director
Kevin Gordon
Independent Director
Jens Holstein
Independent Director
Evan Jones
No Data
About VCYT
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

Webull offers kinds of Veracyte Inc stock information, including NASDAQ:VCYT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCYT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VCYT stock methods without spending real money on the virtual paper trading platform.